Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 10/20 | 0.57 |
| ▸ | CD63 | P08962 | 2/20 | 0.57 |
| ▸ | EPHB4 | P54760 | 9/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | TEK | Q02763 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2481025 | 0.78 | SYK (0.81) | SYKCD63 | |
| SCHEMBL6222008 | 0.78 | EPHB4 (0.53) | SYKCD63EPHB4KDRTEK | |
| SCHEMBL5478121 | 0.78 | EPHB4 (0.64) | EPHB4KDRTEK | |
| SCHEMBL6221467 | 0.77 | EPHB4 (0.52) | SYKCD63EPHB4KDRTEK | |
| SCHEMBL6222910 | 0.77 | EPHB4 (0.47) | SYKCD63EPHB4KDRTEK | |
| SCHEMBL2890179 | 0.76 | SYK (0.68) | SYKCD63 | |
| SCHEMBL2897650 | 0.76 | SYK (0.73) | SYKCD63 | |
| SCHEMBL13212660 | 0.75 | AURKA (0.64) | EPHB4 | |
| SCHEMBL6202976 | 0.75 | EPHB4 (0.84) | SYKEPHB4KDRTEK | |
| SCHEMBL12409242 | 0.74 | TTK (0.56) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275586-A1 | HETEROCYCLIC INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275586-A1 | HETEROCYCLIC INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2008045664-A2 | HETEROCYCLIC PDE4 INHIBITORS AS ANTIINFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275586-A1 | HETEROCYCLIC INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | SYK 2514/4885CD63 4872/4885EPHB4 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.